



1644
34

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

OCT 05 2002

Applicants: Hans Josef Stauss

TECH CENTER 1600/2900

Serial No.: 09/101,413

Art Unit: 1644

Filed: January 17, 1997

Examiner: Ewoldt, G.R.

For: *IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL)*

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including three (3) pages of Form PTO-1449. All of the documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/501,665, filed February 10, 2000, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits after filing of a continuing prosecution application. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 50-1868.

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 91/07509 A1	05-30-1991	Massachusetts Institute of Technology	PCT
WO 95/29995 A1	11-19-1995	The Wistar Institute of Anatomy and Biology	PCT
WO 97/26328 A1	07-24-1997	RPMS Technology Limited	PCT
WO 00/06602 A1	02-10-2000	H. Sugiyama	PCT
WO 00/18795 A2	04-06-2000	Corixa Corporation	PCT
10 218093	07-31-1999	H. Sugiyama	JP

Publications

AL-OBEIDI, et al., "Peptide and peptidomimetic libraries," *Molecular Biotechnology* 9:205-223 (1998).

BEELEY, "Peptidomimetics and small-molecule drug design: towards improved bioavailability and *in vivo* stability," *TIBTECH* 12:213-216 (1994).

BLUYSSSEN, et al., "The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility," *Eur. J. Biochem* 220: 395-402 (1994)

BOTTGER, et al., "Molecular characterization of the hdm2-p53 interaction," *J Mol Biol* 269:744-756 (1997).

BUCKLER, et al., "Isolation, Characterization, and Expression of the Murine Wilms' Tumor Gene (WT1) During Kidney Development," *Molecular and Cellular Biology* 11(3): 1707-1712 (1991).

CROSSLEY & ORKIN, "Phosphorylation of the Erythroid Transcription Factor GATA-1," *J Bio Chem* 269:16589-96 (1994).

GAIGER, et al., "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," *Blood* 96(4):1480-89 (2000).

GAO, et al., "Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specif for WT1," *Blood* 95:2198-2203 (2000).

JANEWAY, et al., *Immunobiology* 4th Edition (Austin et al., eds.), pages 121, 551, 569, Figures 4.3, 4.5 and 4.7, Garland Press 1999

KIEBER-EMMONS, et al., "Therapeutic peptides and peptidomimetics," *Curr Opinion Biotechnol* 8:436-441 (1997).

MEZIERE, et al., "In vivo helper cell response to retro-inverso peptidomimetics," *Journal of Immunology* 159:3230-37 (1997).

MURALI & GREENE, "Structure-based design of immunologically active therapeutic peptides," *Immunologic Research* 17(1&2):163-169 (1998).

NAKANISHI, et al., "Peptidomimetics of the immunoglobulin supergene family – a review," *Gene* 137:51-56 (1993).

OHMINAMI, et al., "HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide," *Blood* 95:286-93 (2000).

OKA, et al., "Cancer immunotherapy targeting Wilms' Tumor Gene WT1 product," *J Immunol* 164:1873-80 (2000).

OKA, et al., "Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms tumor (WT1) product," *Immunogenetics* 51:99-107 (2000).

SADOVNIKOVA & STAUSS, "Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy," *Proc Natl Acad Sci USA* 93:13114-13118 (1996).

SEMBA, et al., "cDNA cloning and its pronephros-specific expression of the Wilms' tumor suppressor gene, WT1, from *Xenopus laevis*," *Gene* 175: 167-172 (1996).

SHARMA, et al., "Molecular Cloning of Rat Wilm's Tumor Complementary DNA and a Study of Messenger RNA Expression in the Urogenital System and the Brain," *Cancer Research* 52: 6407-6412 (1992).

U.S.S.N.: 09/101,413
Filed: January 17, 1997
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea/L. Pabst
Reg. No. 31,284

Dated: September 27, 2002


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 09/101,413
Filed: January 17, 1997
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: September 27, 2002



Erica C. Boughner

ATL1 #545682 v1